-
-
-
The FDA has recently issued stronger warnings on a number of commonly used drugs:
-
The anti-arrhythmic dronedarone has been approved by the FDA for maintenance of normal sinus rhythm in patients with a history of atrial fibrillation or atrial flutter.
-
The FDA has approved prasugrel, a new oral antiplatelet agent for use in preventing thrombosis in patients with acute coronary syndrome who are to be managed by angioplasty.
-
Two papers presented at the recent American Society of Clinical Oncology (ASCO) have brought to light to potential serious drug interaction between tamoxifen and several commonly used SSRI antidepressants.
-
The FDA has approved a single-dose formulation of Plan B, the emergency contraceptive previously available in a two-tablet dose.
-
Tamoxifen and CYP2D6 inhibitors, FDA Actions, and FDA Warnings.
-
For patients with chronic insomnia, sleeping pills in combination with cognitive behavioral therapy (CBT) resulted in improved sleep satisfaction during acute therapy, but long-term treatment was enhanced by stopping the medication and continuing only CBT.
-
Healthy skepticism is warranted before making or accepting a diagnosis of piriformis syndrome.